Skip to main content

Clinolipid Side Effects

Generic name: fat emulsion

Medically reviewed by Drugs.com. Last updated on Dec 14, 2023.

Note: This document contains side effect information about fat emulsion. Some dosage forms listed on this page may not apply to the brand name Clinolipid.

Applies to fat emulsion: intravenous emulsion.

Serious side effects of Clinolipid

Along with its needed effects, fat emulsion (the active ingredient contained in Clinolipid) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking fat emulsion:

More common

Less common

Rare

Incidence not known

Other side effects of Clinolipid

Some side effects of fat emulsion may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Rare

Incidence not known

For Healthcare Professionals

Applies to fat emulsion: intravenous emulsion.

Cardiovascular

Adult patients:

Common (1% to 10%): Hypertension

Uncommon (0.1% to 1%): Tachycardia

Pediatric patients:

Common (1% to 10%): Tachycardia

Uncommon (0.1% to 1%): Hypertension

Postmarketing:

Frequency not reported: Palpitations, phlebitis[Ref]

Gastrointestinal

Adult patients:

Common (1% to 10%): Nausea, vomiting, flatulence, abdominal pain, dyspepsia

Uncommon (0.1% to 1%): Diarrhea

Pediatric patients:

Common (1% to 10%): Vomiting, diarrhea, abdominal pain[Ref]

Dermatologic

Adult patients:

Uncommon (0.1% to 1%): Rash, pruritus

Pediatric patients:

Uncommon (0.1% to 1%): Rash

Postmarketing:

Frequency not reported: Hyperhidrosis[Ref]

General

The most common adverse events in pediatric patients were anemia, vomiting, increased gamma-glutamyl transferase, and nosocomial infection.

Genitourinary

Adult patients:

Common (1% to 10%): Urinary tract infection[Ref]

Hepatic

Adult patients:

Common (1% to 10%): Increased blood bilirubin

Uncommon (0.1% to 1%): Cholestasis, liver function test abnormalities, increased gamma-glutamyl transferase

Frequency not reported: Cholecystitis, cholelithiasis

Pediatric patients:

Common (1% to 10%): Increased gamma-glutamyl transferase, cholestasis, hyperbilirubinemia, increased conjugated bilirubin, increased alanine aminotransferase

Uncommon (0.1% to 1%): liver function test abnormalities

Postmarketing:

Frequency not reported: Cholestasis[Ref]

Hematologic

Adult patients

Common (1% to 10%): Anemia

Uncommon (0.1% to 1%): Leukocytosis, increased C-reactive protein

Pediatric patients:

Very common (10% or more): Anemia

Common (1% to 10%): Thrombocytopenia, increased C-reactive protein[Ref]

Nervous system

Adult patients:

Frequency not reported: Dysgeusia, headache, dizziness[Ref]

Metabolic

Adult patients:

Common (1% to 10%): Hyperglycemia, increased blood triglycerides

Uncommon (0.1% to 1%): Increased alkaline phosphatase

Pediatric patients:

Common (1% to 10%): Hyperglycemia

Uncommon (0.1% to 1%): Increased alkaline phosphatase, metabolic acidosis, increased blood triglycerides

Postmarketing:

Frequency not reported: Fatty acid deficiency[Ref]

Other

Adult patients:

Common (1% to 10%): Pyrexia, fever, device related infections, sepsis

Pediatric patients:

Common (1% to 10%): Nosocomial infection, pyrexia, sepsis

Uncommon (0.1% to 1%): Infection, fluid overload

Postmarketing:

Frequency not reported: Chills, malaise[Ref]

Respiratory

Adult patients:

Uncommon (0.1% to 1%): Dyspnea, pneumonia

Postmarketing:

Frequency not reported: Dyspnea, chest pain[Ref]

References

1. Product Information. Intralipid (fat emulsion, intravenous). Baxter I.V. Systems Division. 2018.

2. Product Information. Smoflipid (fat emulsion, intravenous). Fresenius Kabi USA, LLC. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.